Steroids
2 mechanisms of action
1/ Genomic (activates @ 7.5mg-30mg Pred/day). Ceiling of saturation > 50mg. Limited additional anti-Inflammatory benefit beyond & ⬆️ Adverse
2/ NonGenomic. Act @ 100mg, Max sat 250-500mg & Less S/E as Shorter ⌛️
Less Is More! Great Slide 👇
#Anifrolumab for #Sjogren. Small RCT study noted improved CRESS, cSTAR, ESSPRI, ESSDAI. No issues with safety, no change in histology score, but MxA expression reduced in ANI group #EULAR26#Plenary@RheumNow
Considering non-myopathic causes of elevated CK before initiating an extensive neuromuscular workup is essential for diagnostic efficiency, patient safety. Up to 1.3% of the general population exhibits asymptomatic or oligosymptomatic hyperCKemia, #eular2026#london#autoimmune
#EULAR2026 OP0126 Long-term extension study up to 108 weeks: Ianalumab demonstrated sustained efficacy (change in ESSDAI) including those who switched from PBO to IAN in #Sjogren. IAN improved most domains apart from lungs, MSK & Haem - important to note @RheumNow#EULARBest
#EULAR2026 OP0125 It’s a case of “teamwork makes the dream work!” Instead of an index to capture heterogeneity in #Sjogren activity, the NECESSITY validated using data from 16 RCTs that a new composite tool, STAR has high sensitivity & specificity. Vital for use in RCTs @RheumNow
Consultants in England are “quiet quitting” or looking to escape to Canada and Australia because they feel undervalued and disrespected, senior NHS doctors warn
https://t.co/l2v5SE5E62
https://t.co/QCVxEILYkl
At Week 52 with izokibep in #PsA PASI90: 63–69%; PASI100: 55–64%; MDA: 47–52%. The small-molecule format may enable deeper tissue penetration. Novel anti-IL-17 approach. Abstr#073 @RheumNow#EULAR2026#Biologics
Presented at #EULAR2026:
In a phase 3 trial, obexelimab led to a lower risk of disease flares than placebo among patients with IgG4-related disease. Glucocorticoid use was lower and the incidence of remission was higher with obexelimab than with placebo. Full INDIGO trial results: https://t.co/Lynf6nmA9N
Editorial: Obexelimab and the Promise of Nondepleting B-Cell Therapy in IgG4-Related Disease https://t.co/BUQ7r8jVWz
@eular_org